Products for Research Use Only
RegisterLogin

CBL0137

CAT: 0804-HY-18935-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18935-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-κB and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis[1].
CAS Number
1197996-80-7
Product Name Alternative
Curaxin 137; CBL-C137
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Histone Acetyltransferase; MDM-2/p53; NF-κB
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CBL-0137.html
Concentration
10mM
Purity
99.73
Solubility
DMSO : 11.11 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC(NCCN1C2=C(C3=C1C=CC(C(C)=O)=C3)C=C(C(C)=O)C=C2)C
Molecular Formula
C21H24N2O2
Molecular Weight
336.43
Precautions
H302, H315, H319, H335
References & Citations
[1]Barone TA, et al. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro Oncol. 2017 Feb 1;19 (2) :186-196. h|[2]Burkhart C, et al. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget. 2014 Nov 30;5 (22) :11038-53.|[3]Ehteda A, et al. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep. 2021 Apr 13;35 (2) :108994.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Citation 01
Cell Death Dis. 2024 Oct 27;15 (10) :779.|Eur J Med Chem. 2024 Apr 15:270:116377.|J Neuroinflammation. 2025 Oct 27;22 (1) :243.|Nano Today. 2025 Oct.|Adv Mater. 2024 Jul;36 (29) :e2313991.|Cancer Res. 2021 Jun 1;81 (11) :3105-3120.|Cell Death Dis. 2020 Dec 2;11 (12) :1029.|Cell. 2024 Dec 26;187 (26) :7533-7550.e23.|Mol Med Rep. 2024 Nov;30 (5) :209.|Oncogene. 2023 Jan;42 (1) :11-25.

Alternative Products

CatalogName
206703CBL0137
C3192-5CBL0137 (hydrochloride)
MBS3607178-01CBL0137 hydrochloride
A17143-100CBL0137 100mg
A17143-25CBL0137 25mg

Popular Products